inositol has been researched along with Hyperlipoproteinemia Type II in 3 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
Excerpt | Relevance | Reference |
---|---|---|
"The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
"The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
"One patient with familial hypercholesterolemia (untreated total cholesterol 800 mg%) received a combined drug treatment during 5 years." | 1.26 | Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1980) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hutt, V | 3 |
Wechsler, JG | 3 |
Klör, HU | 3 |
Ditschuneit, H | 3 |
3 other studies available for inositol and Hyperlipoproteinemia Type II
Article | Year |
---|---|
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; I | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipopro | 1980 |